Narva clinics has been acquired by Narva Åderbråckscenter AB
The founder and some key employees of Åderbråcksspecialisterna Narva Kirurg Center AB and Narva Derma Center AB (Narva) have completed an MBO.
Åderbråcksspecialisterna Narva Kirurg Center and Narva Derma Center are engaged in varicose vein treatments and aesthetic skincare. Founded in 2012, Narva is a leading Swedish pioneer in modern endovenous treatments for varicose veins. Most of its income comes from private paying patients but Narva is also one of only two market players contracted by the region of Stockholm to carry out varicose vein treatments. Based in Stockholm, Narva also operates several clinics around the country.
Narva Åderbråckscenter AB is a newly created company owned by Narva’s founder together with key employees. The new shareholders will develop Narva’s business plan in order to take advantage of the market opportunities within privately funded healthcare.
Oaklins’ team in Sweden acted as financial advisor in this transaction.
Stefan Nydahl
Founder, Narva Åderbråckscenter AB
Prata med transaktionsteamet
Relaterade transaktioner
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer